Citius Pharmaceuticals, Inc. reported its first product revenue of $3.9 million in the first quarter of 2026, marking a significant milestone following the December 2025 commercial launch of LYMPHIR™. The drug, developed by Citius Oncology—a majority-owned subsidiary—received regulatory approval for treating relapsed or refractory cutaneous T-cell lymphoma and has begun generating sales through an established network of national distributors.
The company has bolstered its financial position with a $20.9 million equity financing round to support operational growth and pipeline advancement. Beyond LYMPHIR™'s market entry, Citius is progressing late-stage development candidates Mino-Lok and Halo-Lido through clinical trials while evaluating expansion opportunities in international markets and potential combination therapy applications.
The achievement represents a transition for the company from a development-stage entity to a revenue-generating pharmaceutical business, positioning it to pursue additional clinical and commercial objectives across its oncology portfolio.